Trial Profile
A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rimtuzalcap (Primary)
- Indications Essential tremor
- Focus Adverse reactions
- Acronyms Cadence-1
- Sponsors Cadent Therapeutics
- 06 Feb 2020 According to an Cadent Therapeutics media release, this study will be highlighted in a poster presentation at the 3rd Pan American Parkinson's Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami.
- 22 Oct 2019 Status changed from recruiting to completed.
- 17 Oct 2019 Results presented in the Cadent Therapeutics media release.